Search the Newsreel

IMRN|Immuron Ltd|Price:1.110|Chg%:-0.060

This TradingKey analysis of Immuron Ltd (IMRN) focuses on its stock performance and proprietary stock score. The article details how TradingKey generates its comprehensive stock score based on 34 indicators across six dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and …

Immuron CEO Steven Lydeamore Presents at TechKnow Invest Roadshow as Company Advances Polyclonal Antibody Pipeline

Immuron Limited's CEO, Steven Lydeamore, presented at the TechKnow Invest Roadshow, highlighting the company's progress in oral polyclonal antibody therapies. The presentation covered their commercial product Travelan® for travelers' diarrhea, the investigational drug IMM-529 for recurrent Clostridioides difficile infection, and the distributed product ProIBS® …

Immuron (NASDAQ: IMRN) outlines FY26 growth, cash runway and CDI IND plans

Immuron Limited shared an investor update detailing FY26 sales, cash position, and plans for its clinical assets. The company reported global sales revenue of A$7.7 million for FY26, a 6% increase from the previous year, and maintains a strong cash balance of A$10.0 million …

Immuron Ltd (IMRN) Institutional Confidence

This article focuses on the institutional confidence in Immuron Ltd (IMRN), detailing the shareholding and activity of various financial institutions. Key institutions like Morgan Stanley & Co. LLC and Citadel Advisors LLC significantly increased their holdings, while others like XTX Markets LLC and Rhumbline …

Immuron Ltd (IMRN) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Immuron Ltd (IMRN), indicating a "Buy" rating based on one analyst's assessment. The target price for IMRN is set at USD 5.00, representing a significant upside. The report includes current market data and a peer comparison, but …

Immuron Ltd (IMRN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Immuron Ltd (IMRN), focusing on its volatility, financial risk, and investment risk based on various metrics. It details the company's market performance, including daily returns, drawdowns, Sharpe Ratios, and different measures of volatility and liquidity. The data …

Immuron Ltd (IMRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Immuron Ltd (IMRN), focusing on various indicators and moving averages. It presents a summary of "Sell," "Neutral," and "Buy" signals from nine common technical indicators and six moving averages. The analysis concludes with a "Neutral" signal based …

Immuron Ltd (IMRN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Immuron Ltd (IMRN) for Fiscal Year 2023, showcasing its business segments and regional contributions. Travelan accounts for the vast majority of revenue at 96.68%, with Protectyn making up the remaining 3.32%. Geographically, Australia generates 64.31% of revenue, …

Immuron Ltd (IMRN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Immuron Ltd (IMRN). It states that the company has distributed a total of $0.00 in dividends over the past five years and shows "No Data" for specific dividend dates. The article includes …

Immuron Ltd (IMRN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Immuron Ltd (IMRN), listing major individual and institutional holders as of recent reporting periods. It highlights the proportion of shares held by entities such as Morgan Stanley, Citadel Advisors, and XTX Markets, alongside a breakdown by shareholder …

Immuron’s Travelan uses oral antibodies to reduce diarrhea risk

Immuron (NASDAQ: IMRN; ASX: IMC) announced that CEO Steven Lydeamore would present at a Kalkine Media Webinar on July 20, 2026, to discuss the company's developments in orally delivered targeted polyclonal antibodies for infectious diseases. Their flagship product, Travelan (IMM‑124E), is designed to prevent …

Immuron CEO Steven Lydeamore to Present at TechKnow Invest Roadshow in Melbourne

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced that CEO Steven Lydeamore will present at the TechKnow Invest Roadshow in Melbourne on July 27, 2026. He will discuss the company's immunotherapy products, including its key commercial product Travelan® for travelers' diarrhea …

Immuron Limited (NASDAQ: IMRN) highlights antibody platform at TechKnow Invest

Immuron Limited announced that its CEO, Steven Lydeamore, will present at the TechKnow Invest Roadshow to highlight the company's orally delivered targeted polyclonal antibody platform. The presentation will cover its products like Travelan for travelers' diarrhea and IMM-529 for recurrent C. difficile infection, and …

Immuron CEO Steven Lydeamore to Unveil Strategic Vision at Kalkine Media Webinar on July 20, 2026

Immuron Limited (ASX: IMC; NASDAQ: IMRN) CEO Steven Lydeamore will present the company's strategic vision at a Kalkine Media Webinar on July 20, 2026, at 12:30 PM AEST. He is expected to discuss the company's clinical pipeline and commercial products, including its flagship traveler's …

Immuron Limited (NASDAQ: IMRN) grows FY26 revenue to A$7.7m

Immuron Limited reported FY26 global sales revenue of A$7.7 million, a 6% increase from the previous year, driven by strong growth in Australia and the US. The biopharmaceutical company is pursuing a strategic shift towards partnering its clinical assets, IMM-124E and IMM-529, to reduce …

Immuron CEO to Present Company Strategy at Kalkine Media Webinar

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced that CEO Steven Lydeamore will virtually present the company's strategy at the Kalkine Media Webinar on July 20, 2026, at 12:30 PM AEST. The presentation will cover its clinical pipeline and commercial products, …

Immuron FY26 sales rise 6% to AUD$7.7 million led by Australia

Immuron Limited reported a 6% increase in global revenue to AUD$7.7 million for FY26, driven by four consecutive quarters of sales growth, primarily stemming from strong performance in Australia. Australian sales rose 10% to AUD$5.8 million, while U.S. sales grew 7% in AUD terms …

Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year

Immuron Limited reported continued sales growth for Travelan® in FY26, with global sales reaching AUD$7.7 million, a 6% increase from the prior comparative period. Australia saw a 10% sales increase, driven by marketing and new store growth, while US sales increased by 7% in …

Immuron Reports FY26 Global Sales Up 6% on Strong Travelan Growth in Australia and the U.S.

Immuron Limited reported a 6% increase in global sales to AUD$7.7 million for FY26, driven by strong growth of its immune supplement Travelan in Australia and the U.S. Australian sales rose by 10% and U.S. sales by 7% (AUD) or 13% (USD), attributed to …

Immuron 4Q Sales A$2.0M >IMRN

Immuron reported fourth-quarter sales of A$2.0 million. This financial update provides a snapshot of the company's recent sales performance.

Immuron (NASDAQ: IMRN) lifts FY26 Travelan sales 6% to AUD$7.7m

Immuron's Travelan Sales Grow for Four Straight Quarters

Immuron Limited reported unaudited global Travelan sales of AUD$7.7 million for FY26, a 6% increase from the prior comparative period, marking four consecutive quarters of growth. This growth was fueled by strong performances in Australia and the USA, driven by digital marketing and Amazon …